Whitepaper
Enabling complete, prospective real-world evidence (RWE) at scale
Life sciences organizations increasingly rely on proprietary data, such as device telemetry, specialty pharmacy records, and disease registries, to understand how products perform in real-world settings. Yet these data often lack the longitudinal clinical context needed to support regulatory, payer, and product decisions.
Truveta Live Link addresses these challenges by enabling secure, privacy-preserving linkage of proprietary first-party data with Truveta’s real-time longitudinal data in a single, self-governed environment. Live Link enables complete, decision-ready real-world evidence by supporting prospective research and sustained longitudinal follow-up—without rebuilding data pipelines for each analysis.
This white paper examines how Live Link converts fragmented proprietary data into a strategic evidence asset, enabling decision-ready insights across development, access, and post-approval programs.
Download the whitepaper to learn how to:
- Optimize completeness for regulatory- and payer-grade real-world evidence.
- Power prospective real-world research and long-term follow-up.
- Accelerate HEOR, device performance evaluation, label expansion, and safety monitoring.
- Construct concurrent external control arms at population scale and establish long-term follow-up in pragmatic trials.
